2020 Revenues ($USD) : $4,521,371,043
2020 Revenues (foreign currencies) : JP¥482,792,000,000
2020 R&D spend : $867,269,152
2020 Number of Employees : 3,023
Fiscal Year End : 3/31/2020
Key People : Hiroshi Nomura, CEO

Formed in 2005 from the merger of Dainippon Pharmaceutical Co. and Sumitomo Pharmaceuticals, Sumitomo Dainippon Pharma has focused on boosting flexibility and efficiency in recent years. The company has a goal of establishing its position as a "Global Specialized Player" by 2033, according to its 2020 annual report. Focus areas include psychiatry and neurology, diabetes, respiratory and infectious diseases. –CN